Medexus Pharmaceuticals Inc. (MDP.TO) Research

Medexus Pharmaceuticals Inc. operates as a specialized pharmaceutical company, conducting its business across Canada and the United States. The firm's strategic focus encompasses critical therapeutic domains such as oncology, hematology, rheumatology, autoimmune disorders, and allergy treatments. Among its principal offerings are Rasuvo and Metoject, which are methotrexate formulations designed for managing rheumatoid arthritis and various autoimmune conditions. Medexus also provides IXINITY, an intravenous recombinant factor IX therapeutic specifically for patients aged 12 and older suffering from Hemophilia B, along with Rupall, a prescription medication for allergy relief. The company's broader product portfolio includes Treosulfan, a bifunctional alkylating agent utilized in allogeneic hematopoietic stem cell transplantation; Trispan, an injectable suspension containing triamcinolone hexacetonide; and Gleolan, an optical imaging agent indicated for individuals presenting with glioma symptoms. Initially known as Pediapharm Inc., the company rebranded to Medexus Pharmaceuticals Inc. in December 2018. Its corporate headquarters are located in Bolton, Canada.

Open Medexus Pharmaceuticals Inc. (MDP.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.